News Updates

Ipsen and Marengo Therapeutics announced a multi-year partnership to advance the latter's two T cell immuno-oncology candidates from the early preclinical assessment stage into the clinic. Marengo will be eligible to receive an upfront payment of $45 million and potential milestone payments of up to $1.592 billion dependent on the achievement of all milestones, as well as tiered royalties. BioSpace (San Francisco) (8/1)